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ABSTRACT Lactoferrin (LF), an iron-binding glycoprotein
present in milk and other endocrine and exocrine secre-
tions, may exert a number of physiologic effects in the
intestines. To study the effects of oral LF supplementation
in vivo in the gastrointestinal tract, information about the
gastric survival of LF in vivo is important. We tested 12
healthy volunteers (age 21 6 0.3 y) on 3 separate d accord-
ing to a randomized, cross-over design. A test drink con-
taining 4.5 g of bovine LF (20% iron-saturated LF; apoLF) in
the presence of a gastric pH buffer (0.1 mol/L sodium ci-
trate/citric acid; apoLFbuf), apoLF without the buffer
(apoLF) or iron-saturated LF (holoLF) was administered into
the stomach using nasogastric intubation. Gastric empty-
ing rate, determined by a marker dilution technique, did not
differ among any of these drinks. Gastric survival of LF,
analyzed by gel permeation chromatography under dena-
turing conditions, was 64%, 62% and 79% after consump-
tion of the apoLFbuf, apoLF and holoLF test drinks, respec-
tively. Addition of the gastric pH buffer initially lowered
intragastric pH because of its hydroxide buffering effect.
However, it did not elevate intragastric pH over a prolonged
period and thereby inhibit intragastric LF breakdown. We
conclude that after oral administration, substantial
amounts of apoLF and holoLF survive gastric transit. J.
Nutr. 131: 2101–2104, 2001.
KEY WORDS: c lactoferrin c breakdown c gastric emptying
c biological activity c stomach
Lactoferrin (LF)3 is a protein of the transferrin family. It is
present in milk, saliva, tears, bile, blood plasma and mucosal
and genital secretions (1,2). LF binds ferric iron (Fe31) with a
high affinity, even in an acidic environment (3,4). Because of
this strong iron-binding capacity, a number of physiologic
effects have been proposed, as reviewed extensively by several
investigators (2,4–6).
LF has been proposed to act as an antioxidant (7–9). Iron
bound to LF may not be able to catalyze Fenton chemistry.
This, however, has not yet been investigated in vivo. LF is also
involved in the immune system of the body. It is released by
neutrophil-specific granules (7). Other cells of the immune
system, macrophages and monocytes, can bind LF by specific
LF receptors on their cell surfaces, which enable the presence
of LF at sites where the immune system is active. Several
studies have shown a regulatory function of LF on interleu-
kin-6 and tumor necrosis factor-a in vivo in mice (10,11). In
addition, LF was shown to exert antibacterial activity in vivo
(12,13) in mice and recently, LF ingestion with food was
shown to facilitate a recovery from dermophytosis in guinea
pigs (14). LF has been proposed to serve a role in facilitating
iron absorption from the gut by a mechanism that is still poorly
understood. Previously, both a facilitating effect (15) and an
inhibitory effect (16) of LF on iron absorption were described.
These findings indicate that LF supplementation may be of
value in patients prone to intestinal damage, such as people
undergoing oral iron therapy, patients with inflammatory
bowel disease or patients suffering from intestinal stress in
general.
The effects of oral LF supplementation could be potentially
diminished to a certain extent by gastrointestinal breakdown
of the LF molecule. It is not known to what extent LF is
digested in the stomach or in the intestines in vivo. In vitro
incubation of LF with proteolytic enzymes results in the for-
mation of several LF fragments. It was shown that LF is less
rapidly digested in gastric juice than casein and transferrin in
an acidic environment (17). An important factor interfering
with this degradation process is the degree of iron saturation of
the LF. Twenty percent iron-saturated LF (apoLF) is more
easily digested than 100% iron-saturated LF (holoLF) (18,19).
Because the biological activity of LF is located in the intestine,
it is necessary to study the survival of the molecule during
passage through the stomach.
The present study was designed to determine the extent of
gastric degradation of LF in vivo. In addition, the effect of
buffering gastric pH on the breakdown of LF was studied.
MATERIALS AND METHODS
Subjects. Twelve healthy volunteers (five men, seven women,
age 21.3 6 0.3 y) without a history of gastrointestinal complaints
were recruited for this study. All subjects received full information
about the protocol and gave their written informed consent before
participation. This study was approved by the Ethics Committee of
Maastricht University (Maastricht, The Netherlands).
Protocol. Subjects were tested according to a randomized, cross-
over design with a washout period of at least 7 d. On the evening
before testing, all subjects were instructed to consume a standardized
meal ad libitum (rice and sweet/sour sauce; Uncle Ben, Veghel, The
Netherlands). After an overnight 12-h fast, subjects arrived at the
laboratory and remained seated until the end of the experiment.
After arrival, a nasogastric tube was inserted. The stomach was
1 Supported by DMV International, Veghel, The Netherlands.
2 To whom correspondence should be addressed. E-mail: f.troost@hb.
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3 Abbreviations used: apoLF, 20% iron-saturated LF; apoLFbuf, 20% iron-
saturated LF in the presence of a gastric pH buffer; AUC, area under the curve;
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emptied via the nasogastric tubing and rinsed with water until no
additional residue was obtained. A recovery test was performed for
control of the tube tip position (20). Forty-five minutes after gastric
aspiration, a liquid test drink (composition described below) was
administered into the stomach through the tube. Subsequently, the
double sampling technique to determine gastric emptying rate of a
test drink was applied. This method was described in detail previously
(21–23). According to this technique, 188 mg of the inert marker
polyethylene glycol (PEG; PEG 4000; Sigma, Deisenhofen, Ger-
many) was added to each test meal. After ingestion of the test drink,
gastric contents were mixed thoroughly by aspiration and reinjection
of gastric contents for 1 min and 5 mL of gastric contents were
sampled for measurement of total gastric content volume. At each
10-min interval, 2.5 mL of the gastric contents were aspirated and 5
mL PEG solution (60 g/mL water) were added to the gastric contents
via the nasogastric tube. Subsequently, gastric contents were mixed
thoroughly, and 2.5 mL were aspirated. This protocol was followed at
10, 20 and 30 min after administration of the test drink. The PEG
concentration before and after addition of the PEG solution was
measured. From these data, the total volume of gastric contents at
each time point was calculated (23). Also, the amount of test meal
still present in the stomach and the amount of gastric secretion per
10-min intervals was calculated using calculations as described by
Beckers et al. (21). In the samples obtained at 10-min intervals before
adding the PEG solution, the amount of intact LF was determined as
described below. After aspiration, each sample was put directly into
liquid nitrogen and stored at 280°C until analysis to stop degradation
processes after sampling.
Test drinks. Three test drinks were investigated in a randomized,
cross-over order. Each beverage consisted of 300 mL of 80 g/L
maltodextrin (MD20; AVEBE, Veendam, The Netherlands) solution
in water with 4.5 g bovine LF (DMV International, Veghel, The
Netherlands) dissolved. The LF had an iron saturation of ;20%
(apoLF) and 100% (holoLF). ApoLF was ingested on two occasions;
once without a buffer (apoLF) and once in the presence of citrate to
buffer gastric pH (apoLFbuf). The citrate buffer was prepared by
mixing 0.1 mol/L citric acid monohydrate with 0.1 mol/L trisodium-
citrate dihydrate in a volume ratio of 56:44 mL/L test drink, respec-
tively. Citric acid was purchased from Merck (Darmstadt, Germany)
and trisodiumcitrate was purchased from Ferak (Berlin, Germany).
Analytical methods. PEG concentration in the gastric juice
samples was determined spectrophotometrically using a spectronic
1001 device (Bausch en Lomb, Bergen op Zoom, The Netherlands).
Carbohydrates and proteins were removed by precipitation. In the
test drinks and in each sample, pH was measured using a standard pH
analyzer (Radiometer, Copenhagen, Denmark).
A new method was developed and validated to measure LF and LF
digestion fragments in gastric samples. This method uses gel perme-
ation chromatography under denaturing conditions. We found that
LF degradation may proceed on the column in samples containing a
relatively large proportion of gastric juice compared with residual test
drink. When the sample contained . 50% gastric juice, the elution
from the column had to occur within 5 h to prevent LF degradation
by gastric pepsin at the low pH of the elution buffer.
Sample pretreatment: 100 mL gastric juice or LF standard were
mixed with 450 mL 8 mol/L urea (Merck), pH 8.5. After solubiliza-
tion, 450 mL of a mixture of H2O/acetonitrile/trifluoroacetic acid
(600/400/1 v/v) was added. The resulting solution was then filtered
over 0.2 mm PVDF filter (Gelman Sciences, Pall Gelman, Ports-
mouth, ME). Twenty microliters was subsequently applied to the
column (Shodex KW-803; Showa Denko, Tokyo, Japan) and eluted
with the mixture of water/acetonitril/TFA in 25 min at a flow rate of
0.6 mL/min (high performance liquid chromatography; Pharmacia
LKB, Piscataway, NJ). Proteins and peptides were detected at 220
nm. Intact LF eluted after ;11 min, whereas LF fragments eluted
later. Calibration of counts for intact LF was performed with con-
centrations between 1.3 and 13 g/L and a straight line was obtained.
LF fragments between 9 and 80 kDa fitted a straight line obtained
with protein molecular mass markers (LF, bovine serum albumin,
b-lactoglobin, a-lactalbumin and glycomacropeptide).
Calculations. Calculations of gastric emptying and secretion
rates were based on the formulas proposed by Beckers et al. (21). For
these calculations, PEG concentrations in the gastric juice samples
were used to determine gastric content volume at each time point and
gastric secretory rate at 10-min intervals. A gastric emptying curve
was constructed according to a nonlinear regression formula using
specialized software (GraphPad Prism, San Diego, CA). From this
curve, gastric emptying half time of the test drink was determined.
The amount of intact LF entering the intestine was determined by
calculating the area under the curve (AUC) of the gastric emptying
curve and gastric LF concentration. The AUC of the gastric emptying
curve was considered to represent emptying of the ingested amount of
4.5 g LF into the small intestine. Hence, gastric LF breakdown was
calculated by subtracting the AUC of LF breakdown from the AUC
of the gastric emptying curve. LF delivery to the intestines was
calculated by subtracting the gastric LF breakdown from the ingested
amount of 4.5 g LF.
Statistics. Differences in gastric emptying and in gastric pH were
analyzed using one-way ANOVA for repeated measures with Scheffe´
posthoc testing. Differences in LF appearance in the small intestine
among the three drinks were analyzed using ANOVA with the
amount of LF as the dependent variable, test drink as factor and
volunteer as covariate. Differences were considered significant at the
probability level of P , 0.05. All statistical analyses were carried out
using Statview software (SAS Institute, Cary, NC). Values are means
6 SD.
RESULTS
Gastric emptying rate is expressed as gastric emptying half
time (t1/2) of the test drink. Gastric emptying half times were
6.79 6 2.36, 8.46 6 4.07 and 7.03 6 2.14 min for apoLFbuf,
apoLF and holoLF, respectively. Gastric emptying rates did not
differ among any of the test drinks.
The initial pH of the apoLF test drink in the presence of
the pH buffer was 5.95, of the apoLF solution without buffer,
7.12, and of the holoLF solution without buffer, 7.10. Intra-
gastric pH of the apoLF solution with the citrate buffer during
the period of testing was significantly lower directly after
ingestion of the test drink compared with after both the apo-
and the holoLF solutions without buffer (Fig. 1). Ten minutes
after ingestion, intragastric pH was still lower after ingestion of
the apoLF solution with buffer compared with the holoLF, but
not compared with the apoLF drink. Twenty and thirty min-
utes after administration, no differences were observed in
intragastric pH after consumption of any of the test drinks. In
FIGURE 1 Intragastric pH in humans after ingestion of 4.5 g bo-
vine apoLF with citrate buffer (drink 1), 4.5 g bovine apoLF without
buffer (drink 2) and 4.5 g bovine holoLF without buffer (drink 3). All
drinks contain 80 g/L maltodextrin in 300 mL water. Values are means
1 SD, n 5 12. *P , 0.05, drink 1 vs. drink 2; #P , 0.05, drink 1 vs. drink
3.
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addition, no differences in pH were observed at any time
among the nonbuffered test drinks.
After 30 min, all test drinks were nearly completely emp-
tied into the intestine. During this period, 64, 62 and 79%,
respectively, of the LF present in the apoLFbuf, apoLF and
holoLF test drinks entered the intestine in the intact form
(Fig. 2). No differences in LF survival were observed among
any of the test drinks, although the holoLF solution tended to
be more resistant to degradation than the apoLF solution (P
5 0.09).
DISCUSSION
All test drinks were emptied from the stomach at the same
rate. Within ;10 min, half was already emptied. Because of
this rapid gastric emptying of the LF during which only a small
portion of the LF was digested, a large amount of LF entered
the small intestine in the intact form.
Iron binding was shown previously to stabilize the bovine
and human LF molecule (18,19), causing holoLF to be less
susceptible to degradation than apoLF. This was shown after
incubation with trypsin and chymotrypsin. We did not observe
a significant difference in degradation rate among any of the
test drinks, although holoLF tended to be more resistant to
degradation than apoLF (P 5 0.09). This indicates that the
observed difference in susceptibility to degradation between
apo- and holoLF from these in vitro studies is not reflected in
the same manner in our in vivo study of intragastric degrada-
tion of LF, in which pepsin probably is the major cause of LF
degradation. The apoLF used in the present study was 20%
iron-saturated. Considering that iron binding to LF diminishes
the susceptibility of LF to digestion, apoLF containing no iron
may be digested in the stomach more rapidly than the apoLF
used in the present study.
Other investigations showed a minor degradation of LF
both in vivo in the entire digestive tract in newborns (24) as
well as ex vivo in gastric juice of preterm infants (17), al-
though the latter study did show some degradation. In the
present study, we showed partial LF degradation in the adult
gastrointestinal tract in vivo.
Intragastric pH was higher during the first 10 min after
ingestion of both the apo- and the holoLF drink without
citrate buffer compared with the apoLF solution with a 0.1
mol/L sodium citrate buffer. The buffer kept the intragastric
pH relatively constant throughout the test. After 20 min, most
of the citrate buffer was emptied from the stomach with the
rest of the beverage, causing a decrease in buffering capacity
and consequently, intragastric pH was determined mainly by
gastric acid secretion. From in vitro work performed at our
laboratory, we know that LF is resistant to degradation at a pH
above 4. We observed this in an experiment in which we
incubated LF in gastric juice ex vivo. This can partly be
explained by the previous finding that iron is released from LF
at pH lower than 4.0 (25). Iron is stabilizes the LF molecule.
Thus, iron release causes the LF molecule to be more prone to
digestion (18,19). Addition of the citrate buffer did not pre-
vent gastric breakdown of LF in the present study because the
buffer was emptied before it could effectively prevent addi-
tional acidification of gastric contents. Although gastric pH
did not fall below 4.0 until the last 10 min of the experiment,
when most of the test drink was already emptied from the
stomach, we observed a considerable LF breakdown in the
stomach. Hence, intragastric LF digestion in vivo occurs also
at a pH higher than 4.0. This indicates a difference between
the results of in vitro and in vivo experiments.
Intact LF, which has a size of ;79 kDa, consists of two
lobes: the C- and the N-lobe. Incubation of LF with pepsin
leads to formation of a 39.5-kDa fragment, most likely the
C-terminal half of LF (26). After incubation of LF ex vivo in
gastric juice of preterm infants, LF fragments of 33, 34, 41 and
42 kDa were formed, probably also representing half-molecules
of the LF molecule (17). The N-terminal portion of LF was
more prone to digestion by pepsin than the C-terminal half
(27). After incubation with pepsin, the remaining C-terminal
portion of the LF molecule still has iron-binding capacity.
However, after incubation with trypsin and chymotrypsin, two
fragments were obtained; the C-terminal and the N-terminal
portions of LF (26). Both of these LF fragments are still able to
bind iron ions. In other studies, in vitro incubation of LF with
trypsin causes the LF molecule to break down to fragments
with molecular sizes of 20, 30, 40 and 50 kDa (28). In addition,
after LF ingestion in adult mice, LF fragments containing a
peptide called lactoferricin were detected in the feces of these
mice. Lactoferricin, also formed after hydrolysis with pepsin, is
a biologically active component of the LF molecule of ;3.2
kDa. It was shown to have bactericidal activity against Gram-
positive and, especially, against Gram-negative bacteria
(29,30). The lactoferricin shows a stronger antibacterial ac-
tivity than the intact LF molecule, indicating a functional role
of gastric hydrolysis for optimal biological activity (29).
In our study we found LF fragments of several different sizes
at 10 min after ingestion of the test drinks. Most abundant
were fragments with a molecular mass of 76 and 41 kDa,
although we did not quantify these fragments. The presence of
the 76-kDa fragments indicated a rapid hydrolysis of small
parts of the LF molecule. In the present study, we did not
regard LF molecules of 76 kDa or smaller as being intact LF
because any biological activity of intact LF may be different
from the 76-kDa fragments. The 41-kDa fragment probably is
the C-terminal portion of the LF molecule. We did not ex-
amine the precise nature of the fragments. With radial immu-
nodiffusion, we established that immediately after drinking the
test drinks, the recovery of intact LF was 100% (data not
shown). When digestion of LF occurred, as evidenced by the
high performance liquid chromatography pattern, we could
demonstrate that LF fragments larger then 35 kDa still were
able to bind to the antibodies directed against the intact LF
(data not shown).
In this study, LF was intragastrically administered and 45
min before administration, the stomach was rinsed. This was
necessary for the protocol used to measure gastric emptying
and tube tip control. During the 45 min before test drink
ingestion, subjects remained seated. Considering a normal
average gastric juice production of 1500 mL/d, 45 min is
sufficient to restore normal resting gastric juice volume of 50
mL. Theoretically, it is possible that orally administered LF is
FIGURE 2 Total amount of intact bovine LF entering the small
intestine of humans expressed as a percentage of the amount of bovine
LF intragastrically administered. Values are means 1 SD, n 5 12.
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degraded differently from what we found in the present study,
but we believe that the protocol reflects the normal physio-
logical digestive environment.
A number of biological effects are attributed to LF, such as
an antioxidative (7–9), an antiinflammatory, a bactericidal
effect (29–33) and a facilitating role in iron absorption (15).
To exert these effects, LF or biologically active LF fragments
must survive passage through the stomach. To our knowledge,
this is the first study to show that a major proportion of orally
administered bovine LF survives passage through the stomach
in adults. Intragastric degradation is not significantly affected
by the iron saturation of the LF molecule and addition of a
citrate buffer also did not influence breakdown. These findings
are essential in interpreting results of studies concerning bio-
logical effects of LF in the gastrointestinal tract.
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